Please assess the completion status of the following clinical trial:

Trial Title: A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented SARS-CoV-2 infection by qPCR assay performed within the past 7 days~Exclusion Criteria:~* COVID-19 symptoms requiring hospitalization~* PO2 \< 92%~* Short of breath at time of enrollment~* Retinal eye disease~* Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency~* Known chronic kidney disease, stage - 5 or receiving dialysis~* Current use of:~  * Class 3 AAD (amiodarone, dronaderone, dofetilide, sotalol)~ * Class 1A AAD (procainamide, quinidine, disopyramide)~ * Flecainide~ * SSRI: citalopram (Celexa), Escitalopram (Lexapro)~ * chlorpromazine~ * Cilostazol (Pletal)~ * Donepezil (Aricept)~ * Droperidol~ * Fluoconazole~ * Methadone~ * Ondansetron (Zofran)~ * Thioridazine~ * Macrolides (clarithromycin, erythromycin)~ * Fluroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)~ * Tamoxifen~* Pregnancy or women who are breast feeding~* Inability to tolerate oral medications~* Allergy or prior adverse reaction to either hydroxychloroquine sulfate, ribavirin, or nitazoxanide~* Allergy to adhesives~* QTc interval \> 450 mSEC for men and women~* History of Torsade de Pointes VT or prior cardiac arrest or congenital long QT interval~* Non-English-speaking

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Study Drug (Type: ACTIVE_COMPARATOR): 5 day dosing of Nitazoxanide, Ribavirin \& Hydroxychloroquine sulfate
- Placebo (Type: PLACEBO_COMPARATOR): 5 day dosing of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).